Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Controller General of India Calls Industry Meeting On Fixed-Dose Combinations Ban

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - The head of India's Central Drug Control Administration has asked industry associations to discuss a ban on almost 300 fixed-dose drug combinations on June 10, according to a spokesman for the agency, which regulates the manufacture, sale and distribution of drugs

You may also be interested in...



Drug Makers, Indian Regulators Design Plan For Fixed-Dose Phase-out

Indian drug makers and government regulators have designed a formula for determining which of 294 fixed-dose combination dugs are to be phased out of the market. The Confederation of Indian Pharmaceutical Industry reached an agreement with the government to have the industry cease production and marketing of 11 drugs on the government's ban list. The CIPI then is to conduct a product-by-product examination of the drugs for safety and efficacy. (Click here for more

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel